Ideas

Natural product-based therapy for Diabetes Mellitus: Geniposide, isolated from  Gardenia jasminoides, augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 12/April/2019, 10.09 pm
Natural product-based therapy for Diabetes Mellitus: Geniposide, isolated from  Gardenia jasminoides, augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 12/April/2019, 10.09 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more

Ribonucleic acid-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  LncRNA MIAT, Epicatechin and Matrine (MIATEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 21/December/2018,  10.00 pm
Ribonucleic acid-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  LncRNA MIAT, Epicatechin and Matrine (MIATEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 21/December/2018,  10.00 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

read more

PreImplantation Factor (PIF)-based therapy for autoimmune diabetes (TIDM): Synthetic preimplantation factor (sPIF) increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 12/April/2019, 8.31 am
PreImplantation Factor (PIF)-based therapy for autoimmune diabetes (TIDM): Synthetic preimplantation factor (sPIF) increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 12/April/2019, 8.31 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of…

read more

Autologous blood transfusion as a curative therapy for Diabetes Mellitus: Autologous blood transfusion augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 12/April/2019, 8.01 am
Autologous blood transfusion as a curative therapy for Diabetes Mellitus: Autologous blood transfusion augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 12/April/2019, 8.01 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more

Probiotic-based chemotherapy targeting immune-inhibitory receptors and cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: A pharmaceutical mixture encompassing  Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as IL-1β, VHL, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 10/April/2018, 12.09 am
Probiotic-based chemotherapy targeting immune-inhibitory receptors and cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: A pharmaceutical mixture encompassing  Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as IL-1β, VHL, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 10/April/2018, 12.09 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA shows that “Prostaglandin E1 and…

read more

Intracardiac injection of Cyclin helix B peptide (CHBP) protects against Myocardial infarction: Cyclin helix B peptide (CHBP) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 9/April/2019, 11.56 pm
Intracardiac injection of Cyclin helix B peptide (CHBP) protects against Myocardial infarction: Cyclin helix B peptide (CHBP) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 9/April/2019, 11.56 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of the journal Nature,  by Prof Dimmler,…

read more
Start Typing